Chugai Expects Limited Impact From First Biosimilar To Top Seller
First biosimilar version of Avastin approved in Japan, posing the first direct threat to Chugai's top product. But indications and timings mean the company expects limited impact this year.
You may also be interested in...
First Japan legal ruling means biosimilar competition can continue to gnaw away at Rituxan, at least for now, as Chugai faces rising challenges to its mature oncology portfolio.
Trastuzumab, rituximab and bevacizumab are slated for launch later this year as Pfizer builds out its biosimilar oncology offering.
In this week's podcast edition of Five Must-Know Things: major Q4 catalysts; Verona’s COPD contender; Alfasigma acquires Intercept; more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs.